Trial · NCT04088630
Results by group61
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 61
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Cardiac Events | Fingolimod | 3 | Participants | ||
| Number of Participants With Clinically Significant Cardiac Events | Control | 0 | Participants | ||
| Number of Participants With Clinically Significant Cardiac Events | Open-label Fingolimod | 0 | Participants | ||
| Rate of Nosocomial Infections (UTI, Sepsis, and Pneumonia) | Fingolimod | 1 | Participants | ||
| Rate of Nosocomial Infections (UTI, Sepsis, and Pneumonia) | Control | 1 | Participants | ||
| Rate of Nosocomial Infections (UTI, Sepsis, and Pneumonia) | Open-label Fingolimod | 5 | Participants | ||
| Rate of Neurologic Decline | Fingolimod | 2 | Participants | ||
| Rate of Neurologic Decline | Control | 0 | Participants | ||
| Rate of Neurologic Decline | Open-label Fingolimod | 0 | Participants | ||
| Rate of Successful Administration of Fingolimod Through an NGT or Dobhoff Tube | Open-label Fingolimod | 11 | Participants | ||
| Percent Change in Lymphocyte Subpopulations of CD4+ T Cells | Fingolimod | 19.6 | Full Range -18.8 to 81.9 | percent change | |
| Percent Change in Lymphocyte Subpopulations of CD4+ T Cells | Control | -2.56 | Full Range -10.3 to 3.52 | percent change | |
| Percent Change in Lymphocyte Subpopulations of CD4+ T Cells | Open-label Fingolimod | -5.00 | Full Range -14.7 to 40.5 | percent change | |
| Percent Change in Lymphocyte Subpopulations of CD8+ T Cells | Fingolimod | 19.3 | Full Range -20.4 to 59.0 | percent change | |
| Percent Change in Lymphocyte Subpopulations of CD8+ T Cells | Control | 21.4 | Full Range -6.09 to 113 | percent change | |
| Percent Change in Lymphocyte Subpopulations of CD8+ T Cells | Open-label Fingolimod | 21.6 | Full Range -61.5 to 82.9 | percent change | |
| Percent Change in Lymphocyte Subpopulations of CD19+ B Cells | Fingolimod | 121 | Full Range -39.4 to 186 | percent change | |
| Percent Change in Lymphocyte Subpopulations of CD19+ B Cells | Control | 0.230 | Full Range -16.9 to 16.5 | percent change | |
| Percent Change in Lymphocyte Subpopulations of CD19+ B Cells | Open-label Fingolimod | 9.22 | Full Range -84.1 to 43.8 | percent change | |
| Change in Hematoma Volume Obtained by MRI | Fingolimod | -247.19 | Standard Error 75.68 | mm^3 per day |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04088630/results